Clinical Trial Update: Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia Gravis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pyridostigmine with ondansetron in anti-AChR positive myasthenia gravis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis

Drugs mentioned

• Ondansetron (ondansetron)
• Pyridostigmine (pyridostigmine)

Snippet

Sponsor: DAS-MG, Inc | Conditions: Myasthenia Gravis | Phase 2 | Status: TERMINATED